Priavoid aims to become a leading biopharmaceutical company focusing on disorders affecting the Central Nervous System (CNS).

Our global growth strategy has three elements, centered around developing innovative therapies for CNS disorders, with a particular focus on drugs for treatment of Alzheimer’s diseases.

1. Maximize PRI-002 commercial opportunity

We are working to maximize the opportunity for PRI-002, which as the first causal therapy to treat Alzheimer’s disease has the potential to improve the lives of patients around the world. After successfully completing a Phase I clinical trial, we plan to conduct a Phase II clinical trial.


2. Focus development resources on value-creation

To maximize the value of our pipeline, we are utilizing our development resources on our portfolio of CNS drugs. Developing CNS candidates matches best the company’s organizational resources, and allows us to generate substantial benefit for patients suffering from these diseases.


3. Out license or monetize non-core assets

Partnering is an important part of our overall strategy and we are actively talking to potential partners about our innovative pipeline of novel compounds, to ensure these compounds are profiting from the best expertise to bring them to market.


Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice